PubMed Citation (3414 patients with cardiovascular disease were treated with statins and ezetimibe and either ER niacin or placebo and followed for cardiovascular outcomes; niacin use was associated with a rise in HDL cholesterol and fall in triglycerides levels, but clinical outcomes were not affected; adverse events were rare with liver test abnormalities in 0.5% of placebo and 0.8% of niacin recipients).